| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.099 | 0.002 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.004 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.005 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.097 | 0.005 |